Darunavir is a nonpeptidic inhibitor of protease (PR) that lodges itself in the active site of PR through a number of hydrogen bonds. It was developed to increase interactions with HIV-1 protease and to be more resistant against HIV-1 protease mutations. With a Kd (dissociation constant) of 4.5 x 10−12 M, darunavir has a much stronger interaction with PR and its dissociation constant is 1/100 to 1/1000 of other protease inhibitors.
FDA-approved since 2015, approved to treat HIV-1 infection.
. Peptide-like and Small-Molecule Inhibitors Against Covid-19. J Biomol Struct Dyn. 2020 Apr 20;1-15. DOI: 10.1080/07391102.2020.1757510.
Costanzo M, De Giglio MAR, Roviello GN. SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Curr Med Chem. 2020 Apr 16. doi: 10.2174/0929867327666200416131117. PMID: 32297571.